STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

Feed excerpt — reported by STAT News

Novartis' MS drug remibrutinib falls short of Roche’s experimental drug in pivotal trials, but has favorable safety profile.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

View MAP Context →